{"id":23894,"date":"2026-05-04T01:46:00","date_gmt":"2026-05-03T22:46:00","guid":{"rendered":"https:\/\/www.kapa3.gr\/?p=23894"},"modified":"2026-05-04T02:00:20","modified_gmt":"2026-05-03T23:00:20","slug":"additional-rebate-high-cost-medicines-2025","status":"publish","type":"post","link":"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/","title":{"rendered":"Additional Rebate on High-Cost Medicines for 2025: What the New Decision Foresees"},"content":{"rendered":"<div>\n<div class=\"flex h-svh w-screen flex-col\">\n<div class=\"relative z-0 flex min-h-0 w-full flex-1\">\n<div class=\"relative flex min-h-0 w-full flex-1\">\n<div class=\"@container\/main relative flex min-w-0 flex-1 flex-col -translate-y-[calc(env(safe-area-inset-bottom,0px)\/2)] pt-[calc(env(safe-area-inset-bottom,0px)\/2)]\">\n<div class=\"@w-sm\/main:[scrollbar-gutter:var(--stage-scroll-gutter)] touch:[scrollbar-width:none] group\/scroll-root relative flex min-h-0 min-w-0 flex-1 flex-col [scrollbar-gutter:stable] not-print:overflow-x-clip not-print:overflow-y-auto group-data-stream-active\/scroll-root:[overflow-anchor:none] scroll-pt-(--header-height) [--sticky-padding-top:var(--header-height)] [--sticky-padding-bottom:0px] [--scroll-root-safe-area-inset-top:calc(var(--sticky-padding-top)+env(safe-area-inset-top,0px))] [--scroll-root-safe-area-inset-bottom:calc(var(--sticky-padding-bottom)+var(--screen-keyboard-height,0px)+env(safe-area-inset-bottom,0px))] [--scroll-root-safe-area-height:calc(100lvh-var(--scroll-root-safe-area-inset-top)-var(--scroll-root-safe-area-inset-bottom))] has-data-[fixed-header=less-than-xl]:@w-xl\/main:scroll-pt-0 has-data-[fixed-header=less-than-xl]:@w-xl\/main:[--sticky-padding-top:0px] has-data-[fixed-header=less-than-xxl]:@w-2xl\/main:scroll-pt-0 has-data-[fixed-header=less-than-xxl]:@w-2xl\/main:[--sticky-padding-top:0px]\" data-scroll-root=\"\" data-scroll-from-top=\"\" data-scroll-from-end=\"\">\n<p>&nbsp;<\/p>\n<div id=\"thread\" class=\"group\/thread flex flex-col min-h-full\">\n<div class=\"composer-parent flex flex-1 flex-col focus-visible:outline-0\" role=\"presentation\">\n<div class=\"relative basis-auto flex-col -mb-(--composer-overlap-px) pb-(--composer-overlap-px) [--composer-overlap-px:28px] grow flex\">\n<div class=\"flex flex-col text-sm\">\n<section class=\"text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto [content-visibility:auto] supports-[content-visibility:auto]:[contain-intrinsic-size:auto_100lvh] R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\" data-turn-id=\"request-69ec1b90-f71c-8326-93bc-5f8a134ea36c-11\" data-testid=\"conversation-turn-28\" data-scroll-anchor=\"false\" data-turn=\"assistant\">\n<div class=\"text-base my-auto mx-auto [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\">\n<div class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\">\n<div class=\"flex max-w-full flex-col gap-4 grow\">\n<div class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"e132428e-d070-4d90-a5fd-50734502c49f\" data-message-model-slug=\"gpt-5-3-mini\">\n<div class=\"flex w-full flex-col gap-1 empty:hidden\">\n<div class=\"markdown prose dark:prose-invert w-full wrap-break-word light markdown-new-styling\">\n<p data-start=\"292\" data-end=\"518\">With a joint ministerial decision published in the Government Gazette <strong>(FEK B\u2019 2313\/24.04.2026)<\/strong>, a retroactive measure for 2025 establishes an additional rebate on high-cost medicines (HCMs) reimbursed by the healthcare system.<\/p>\n<p data-start=\"520\" data-end=\"969\">The decision concerns specific categories of medicines covered by the National Organization for Healthcare Services Provision (<a href=\"https:\/\/www.eopyy.gov.gr\/\">EOPYY<\/a>), mainly those included in high-expenditure therapeutic clusters or those representing a significant financial burden for the system. For these medicines, an additional 3% reimbursement is introduced, calculated on the producer price and borne by pharmaceutical companies, which is then returned to the Organization.<\/p>\n<p data-start=\"971\" data-end=\"1273\">The amount of the additional rebate on high-cost medicines is calculated based on 2025 consumption data and is paid on a quarterly basis. Specific exemptions are also foreseen for certain medicines, such as those with very low daily treatment cost or those included in special reimbursement agreements.<\/p>\n<h3 data-section-id=\"1xff1pb\" data-start=\"1275\" data-end=\"1308\">What the additional rebate on high-cost medicines means<\/h3>\n<p data-start=\"1310\" data-end=\"1563\">The additional rebate on high-cost medicines does not directly affect patients\u2019 co-payments nor does it change the way medicines are accessed. High-cost medicines continue to be provided under the existing reimbursement framework, as currently in place.<\/p>\n<p data-start=\"1565\" data-end=\"1843\">This regulation is part of the broader policy framework for controlling pharmaceutical expenditure and ensuring the financial sustainability of the healthcare system. Efficient resource allocation remains a key factor in maintaining access to expensive and necessary treatments.<\/p>\n<p data-start=\"1845\" data-end=\"2039\">At the same time, such measures are part of a complex pharmaceutical policy mechanism that influences the overall functioning of the medicines market and the long-term availability of therapies.<\/p>\n<h3 data-section-id=\"1t7kgq6\" data-start=\"2041\" data-end=\"2074\">The importance of information<\/h3>\n<p data-start=\"2076\" data-end=\"2314\">Understanding decisions related to medicines and healthcare financing is an essential part of system transparency. Timely and reliable information helps citizens better understand the framework within which access to treatments is shaped.<\/p>\n<p data-start=\"2316\" data-end=\"2503\">For organizations supporting patients, monitoring such developments is important, as it contributes to a more informed public dialogue on equitable and uninterrupted access to healthcare.<\/p>\n<p data-start=\"2505\" data-end=\"2569\">Read our previous articles on high-cost medicines here and here.<\/p>\n<p data-start=\"2571\" data-end=\"2614\">Read the official Gazette here (in Greek) : <a href=\"https:\/\/www.kapa3.gr\/wp-content\/uploads\/2026\/05\/20260202313-1.pdf\">20260202313<\/a><\/p>\n<p data-start=\"2616\" data-end=\"2662\">Text\/Adaptation: Ifigenia Anastasiou for Kapa3<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; With a joint ministerial decision published in the Government Gazette (FEK B\u2019 2313\/24.04.2026), a retroactive measure for 2025 establishes an additional rebate on high-cost medicines (HCMs) reimbursed by the &hellip; <a href=\"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">Additional Rebate on High-Cost Medicines for 2025: What the New Decision Foresees<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1165,218,1163,1156,1620,891,1166,1777,1778,682],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Additional Rebate on High-Cost Medicines for 2025: What the New Decision Provides<\/title>\n<meta name=\"description\" content=\"A new ministerial decision introduces a retroactive 2025 additional rebate on high-cost medicines reimbursed by the healthcare system in Greece.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Additional Rebate on High-Cost Medicines for 2025: What the New Decision Provides\" \/>\n<meta property=\"og:description\" content=\"A new ministerial decision introduces a retroactive 2025 additional rebate on high-cost medicines reimbursed by the healthcare system in Greece.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"K3\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapa3.k3\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-03T22:46:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-03T23:00:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.kapa3.gr\/wp-content\/uploads\/2021\/06\/kapa-3-social.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"k3-editor\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"k3-editor\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/\"},\"author\":{\"name\":\"k3-editor\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/#\/schema\/person\/bb0605d11e13832c0e59d34ad0afa9d0\"},\"headline\":\"Additional Rebate on High-Cost Medicines for 2025: What the New Decision Foresees\",\"datePublished\":\"2026-05-03T22:46:00+00:00\",\"dateModified\":\"2026-05-03T23:00:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/\"},\"wordCount\":342,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/#organization\"},\"articleSection\":[\"access to treatment\",\"CANCER\",\"chronic conditions\",\"EOPYY\",\"Government Gazette\",\"Greece\",\"Greek healthcare system\",\"HCM\",\"High Cost Medicine\",\"Kapa3\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/\",\"url\":\"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/\",\"name\":\"Additional Rebate on High-Cost Medicines for 2025: What the New Decision Provides\",\"isPartOf\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/#website\"},\"datePublished\":\"2026-05-03T22:46:00+00:00\",\"dateModified\":\"2026-05-03T23:00:20+00:00\",\"description\":\"A new ministerial decision introduces a retroactive 2025 additional rebate on high-cost medicines reimbursed by the healthcare system in Greece.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.kapa3.gr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Additional Rebate on High-Cost Medicines for 2025: What the New Decision Foresees\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/#website\",\"url\":\"https:\/\/www.kapa3.gr\/en\/\",\"name\":\"K3\",\"description\":\"\u039a\u0395\u039d\u03a4\u03a1\u039f \u039a\u0391\u0398\u039f\u0394\u0397\u0393\u0397\u03a3\u0397\u03a3 \u039a\u0391\u03a1\u039a\u0399\u039d\u039f\u03a0\u0391\u0398\u03a9\u039d\",\"publisher\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.kapa3.gr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/#organization\",\"name\":\"\u039a\u03ad\u03bd\u03c4\u03c1\u03bf \u039a\u03b1\u03b8\u03bf\u03b4\u03ae\u03b3\u03b7\u03c3\u03b7\u03c2 \u039a\u03b1\u03c1\u03ba\u03b9\u03bd\u03bf\u03c0\u03b1\u03b8\u03ce\u03bd (\u039a3)\",\"url\":\"https:\/\/www.kapa3.gr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.kapa3.gr\/wp-content\/uploads\/2020\/03\/Kapa3-logo.png\",\"contentUrl\":\"https:\/\/www.kapa3.gr\/wp-content\/uploads\/2020\/03\/Kapa3-logo.png\",\"width\":350,\"height\":111,\"caption\":\"\u039a\u03ad\u03bd\u03c4\u03c1\u03bf \u039a\u03b1\u03b8\u03bf\u03b4\u03ae\u03b3\u03b7\u03c3\u03b7\u03c2 \u039a\u03b1\u03c1\u03ba\u03b9\u03bd\u03bf\u03c0\u03b1\u03b8\u03ce\u03bd (\u039a3)\"},\"image\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapa3.k3\",\"https:\/\/www.instagram.com\/kapa3.k3\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/#\/schema\/person\/bb0605d11e13832c0e59d34ad0afa9d0\",\"name\":\"k3-editor\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5838368fc27f3acabd32a77c8dff3dce?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5838368fc27f3acabd32a77c8dff3dce?s=96&d=mm&r=g\",\"caption\":\"k3-editor\"},\"url\":\"https:\/\/www.kapa3.gr\/en\/author\/k3-editor\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Additional Rebate on High-Cost Medicines for 2025: What the New Decision Provides","description":"A new ministerial decision introduces a retroactive 2025 additional rebate on high-cost medicines reimbursed by the healthcare system in Greece.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/","og_locale":"en_US","og_type":"article","og_title":"Additional Rebate on High-Cost Medicines for 2025: What the New Decision Provides","og_description":"A new ministerial decision introduces a retroactive 2025 additional rebate on high-cost medicines reimbursed by the healthcare system in Greece.","og_url":"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/","og_site_name":"K3","article_publisher":"https:\/\/www.facebook.com\/kapa3.k3","article_published_time":"2026-05-03T22:46:00+00:00","article_modified_time":"2026-05-03T23:00:20+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.kapa3.gr\/wp-content\/uploads\/2021\/06\/kapa-3-social.jpg","type":"image\/jpeg"}],"author":"k3-editor","twitter_card":"summary_large_image","twitter_misc":{"Written by":"k3-editor","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/#article","isPartOf":{"@id":"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/"},"author":{"name":"k3-editor","@id":"https:\/\/www.kapa3.gr\/en\/#\/schema\/person\/bb0605d11e13832c0e59d34ad0afa9d0"},"headline":"Additional Rebate on High-Cost Medicines for 2025: What the New Decision Foresees","datePublished":"2026-05-03T22:46:00+00:00","dateModified":"2026-05-03T23:00:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/"},"wordCount":342,"commentCount":0,"publisher":{"@id":"https:\/\/www.kapa3.gr\/en\/#organization"},"articleSection":["access to treatment","CANCER","chronic conditions","EOPYY","Government Gazette","Greece","Greek healthcare system","HCM","High Cost Medicine","Kapa3"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/","url":"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/","name":"Additional Rebate on High-Cost Medicines for 2025: What the New Decision Provides","isPartOf":{"@id":"https:\/\/www.kapa3.gr\/en\/#website"},"datePublished":"2026-05-03T22:46:00+00:00","dateModified":"2026-05-03T23:00:20+00:00","description":"A new ministerial decision introduces a retroactive 2025 additional rebate on high-cost medicines reimbursed by the healthcare system in Greece.","breadcrumb":{"@id":"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kapa3.gr\/en\/additional-rebate-high-cost-medicines-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kapa3.gr\/en\/"},{"@type":"ListItem","position":2,"name":"Additional Rebate on High-Cost Medicines for 2025: What the New Decision Foresees"}]},{"@type":"WebSite","@id":"https:\/\/www.kapa3.gr\/en\/#website","url":"https:\/\/www.kapa3.gr\/en\/","name":"K3","description":"\u039a\u0395\u039d\u03a4\u03a1\u039f \u039a\u0391\u0398\u039f\u0394\u0397\u0393\u0397\u03a3\u0397\u03a3 \u039a\u0391\u03a1\u039a\u0399\u039d\u039f\u03a0\u0391\u0398\u03a9\u039d","publisher":{"@id":"https:\/\/www.kapa3.gr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kapa3.gr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.kapa3.gr\/en\/#organization","name":"\u039a\u03ad\u03bd\u03c4\u03c1\u03bf \u039a\u03b1\u03b8\u03bf\u03b4\u03ae\u03b3\u03b7\u03c3\u03b7\u03c2 \u039a\u03b1\u03c1\u03ba\u03b9\u03bd\u03bf\u03c0\u03b1\u03b8\u03ce\u03bd (\u039a3)","url":"https:\/\/www.kapa3.gr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kapa3.gr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.kapa3.gr\/wp-content\/uploads\/2020\/03\/Kapa3-logo.png","contentUrl":"https:\/\/www.kapa3.gr\/wp-content\/uploads\/2020\/03\/Kapa3-logo.png","width":350,"height":111,"caption":"\u039a\u03ad\u03bd\u03c4\u03c1\u03bf \u039a\u03b1\u03b8\u03bf\u03b4\u03ae\u03b3\u03b7\u03c3\u03b7\u03c2 \u039a\u03b1\u03c1\u03ba\u03b9\u03bd\u03bf\u03c0\u03b1\u03b8\u03ce\u03bd (\u039a3)"},"image":{"@id":"https:\/\/www.kapa3.gr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapa3.k3","https:\/\/www.instagram.com\/kapa3.k3\/"]},{"@type":"Person","@id":"https:\/\/www.kapa3.gr\/en\/#\/schema\/person\/bb0605d11e13832c0e59d34ad0afa9d0","name":"k3-editor","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kapa3.gr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5838368fc27f3acabd32a77c8dff3dce?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5838368fc27f3acabd32a77c8dff3dce?s=96&d=mm&r=g","caption":"k3-editor"},"url":"https:\/\/www.kapa3.gr\/en\/author\/k3-editor\/"}]}},"_links":{"self":[{"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/posts\/23894"}],"collection":[{"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/comments?post=23894"}],"version-history":[{"count":2,"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/posts\/23894\/revisions"}],"predecessor-version":[{"id":23897,"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/posts\/23894\/revisions\/23897"}],"wp:attachment":[{"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/media?parent=23894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/categories?post=23894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/tags?post=23894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}